7.35MMarket Cap-0.47P/E (TTM)
2.4100High2.2701Low116.23KVolume2.4100Open2.3700Pre Close270.69KTurnover3.68%Turnover RatioLossP/E (Static)3.16MShares14.918452wk High1.79P/B7.35MFloat Cap1.830152wk Low--Dividend TTM3.15MShs Float719999.6400Historical High--Div YieldTTM5.90%Amplitude1.8300Historical Low2.3290Avg Price1Lot Size
Soligenix Stock Forum
Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands
Can This New CTCL Treatment Outperform Current Standard of Care? Key Data Coming in March
🚀🚀🚀
Can this stock run like $Phio Pharmaceuticals (PHIO.US)$ and $Salarius Pharmaceuticals (SLRX.US)$ ?
EXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'
Soligenix
Tells Benzinga HyBryte Expanded
Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving "Treatment Success'
Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
'Study Supported by $2.6 Million FDA Orphan Products Development...
No comment yet